Navigation Links
Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology

Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical results referenced in this release may not be indicative of results achievable from testing in humans and that results from one study may necessarily not be reflected or supported by the results of other similar studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of Inovio's technology as a delivery mechanism, the availability or potential availability of alternative therapies or treatments for the conditions targeted by Inovio or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that Inovio and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide Inovio with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether Inovio can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2006, our 10-Q for the three months ending March 31,
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
11. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
Post Your Comments:
(Date:10/22/2014)... 2014   Surefire Medical , Inc., the developer ... maximize targeted delivery of embolization agents in minimally invasive ... John R. Daniels , MD of the University ... oncologist Steven C. Katz , MD of the ... Advisory Board (SAB).    "The role of ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... an August 2014 report by Global Research & Data ... 6.2% per year from 2014 through 2018, as demand ... United States is the world,s largest market ... market with advanced thermometers is Sanomedics International Holdings, Inc. ...
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 /PRNewswire/ ... they have entered into a license and collaboration ... target cancers. PhosImmune possesses technology for ... surfaces of tumor cells in association with HLA ... proteins that play a role in malignancy, are ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
... 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: ... leader in the development, assembly, marketing and sale of ... announced that it will participate in the Arab Health ... 24-27, 2011 at the Dubai World Trade Centre in ...
... Calif., Jan. 11, 2011 Accuray Incorporated (Nasdaq: ... of radiosurgery, announced today the first published five-year outcomes on ... CyberKnife® Robotic Radiosurgery System . The multi-center study, published ... , found that 93 percent of patients had no recurrence ...
Cached Medicine Technology:Dehaier Medical Announces Participation in Arab Health 2011 2First Five-Year Outcomes Published on CyberKnife Radiosurgery for Prostate Cancer 2First Five-Year Outcomes Published on CyberKnife Radiosurgery for Prostate Cancer 3First Five-Year Outcomes Published on CyberKnife Radiosurgery for Prostate Cancer 4
(Date:10/22/2014)... On October 22, CBS will air an ... both fictional and real. The Charles E Holman ... to advocacy and philanthropy in the battle against Morgellons ... to impart truth and clarity about this misunderstood and ... misconceptions about Morgellons Disease (MD) and most ...
(Date:10/22/2014)... 22, 2014 For Dr. Iris Hunter, a ... it’s an extension of her life’s mission. Her extensive experience ... the owner of FirstLight HomeCare, make it clear that Hunter’s ... me that my work makes a difference in the lives ... spirit, so after much research, I felt ready to start ...
(Date:10/22/2014)... 22, 2014 Shriners Hospitals for Children® ... change the current location of Shriners Hospitals for Children ... across from the University of Kentucky Albert B. Chandler ... care center, owned and operated by Shriners Hospitals for ... of children and their families well into the future. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 With the Affordable ... national survey by the American Institutes for Research (AIR) finds ... how to use health insurance, but 42 percent say they ... plan’s details before signing up for coverage. , The AIR ... only 20 percent able to calculate correctly how much they ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2
... tests, but side effects concern researchers , FRIDAY, Jan. ... longer prescribed may find new life as an effective ... as clorgyline, hasn,t been tested in humans as a ... can reduce and even reverse the symptoms of heart ...
... in those who worked out while dieting , THURSDAY, Jan. ... this year, consider adding a regular exercise program while you,re ... outcomes -- such as lower blood pressure and cholesterol levels ... , "It,s better to lose weight with a combination of ...
... sleep nightly, study finds, , FRIDAY, Jan. 8 (HealthDay News) ... teachers of adolescents, a new study finds that most U.S. ... the study found that almost 69 percent of high school ... about 8 percent of teens get the optimal amount -- ...
... messaging from quitline specialists (i.e., stressing the benefits ... those who received standard-care messaging (i.e., potential losses ... a new study published online January 7 in ... . Researchers also established that quitline specialists can ...
... to genetically modify human embryonic stem cells. Their approach, which ... genes, will make possible the rapid development of stem cell ... diseases and as testbeds on which to screen potential treatments, ... whole human embryonic stem cell field. Otherwise, there,s really few ...
... has shown that metformin, a drug often used in the ... patients who have both diabetes and advanced heart failure. The ... by researchers at the David Geffen School of Medicine ... "There may be over two million individuals with heart failure ...
Cached Medicine News:Health News:Older Antidepressant May Treat Heart Failure 2Health News:For Fitness, Cutting Calories May Not Be Enough 2Health News:For Fitness, Cutting Calories May Not Be Enough 3Health News:Two-Thirds of American Teens Need More Shut-Eye 2Health News:Two-Thirds of American Teens Need More Shut-Eye 3Health News:Quitline messages that stress benefits of quitting may improve smoking cessation 2Health News:Biologists develop efficient genetic modification of human embryonic stem cells 2Health News:Biologists develop efficient genetic modification of human embryonic stem cells 3Health News:UCLA study shows metformin is safe for patients with advanced heart failure and diabetes mellitus 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: